Advertisement

Clinical Drug Investigation

, Volume 33, Issue 12, pp 885–891 | Cite as

Pharmacokinetic Characterization of Tizanidine Nasal Spray, a Novel Intranasal Delivery Method for the Treatment of Skeletal Muscle Spasm

  • Daniela Cristina Vitale
  • Cateno Piazza
  • Tiziana Sinagra
  • Vincenzo Urso
  • Francesco Cardì
  • Filippo Drago
  • Salvatore SalomoneEmail author
Original Research Article

Abstract

Background and Objective

The skeletal muscle relaxant tizanidine is approved by the US FDA and the European Medicines Agency for treating spasticity and is supplied as tablets for oral administration. However, tizanidine has a poor bioavailability, due to extensive first-pass metabolism. Therefore, the nasal route of administration, which bypasses portal circulation, may increase the bioavailability of tizanidine and, possibly, reduce the time to peak plasma concentration, thereby shorting the latency of therapeutic effect. The objective of this study was to evaluate the pharmacokinetic profile of tizanidine nasal spray and compare it to the profile of tizanidine oral tablets.

Methods

This open-label, phase I study comprised two protocols: protocol 1, tizanidine HCl solution (32.73 mg/mL) intranasally at single doses of 2 and 4 mg versus 4 mg tizanidine oral tablets (randomized, three periods crossover, 12 healthy subjects); and protocol 2, tizanidine HCl solution (16.36 mg/mL) intranasally at a single dose of 1 mg vs. 4 mg tizanidine oral tablets (randomized, two periods crossover, 12 healthy subjects, one dropout). Tizanidine plasma concentrations were determined by liquid chromatography/mass spectrometry.

Results

There was a linear relationship between different dosages of intranasal formulation and the area under the concentration–time curve and maximum plasma concentration (C max). The relative bioavailability of the different dosages of intranasal formulation were 1.29, 1.93, and 4.23 for 1, 2, and 4 mg intranasal administration, respectively. Comparison of C max values gave the following ratios: 0.91, 1.39, and 2.73, for 1, 2, and 4 mg intranasal administration, respectively. The mean time to C max (t max) was 0.99, 0.43, and 0.63 h for 1, 2, and 4 mg intranasal administration, respectively, whereas it was 1.13 and 1.30 h for the two series of 4 mg tizanidine oral tablets.

Conclusions

The bioavailability of the tizanidine intranasal formulation was higher than that of tizanidine oral tablets. The t max was also shorter with the intranasal formulation. No serious adverse events occurred throughout the study, such that the two formulations resulted equally well-tolerated. The intranasal formulation of tizanidine results are therefore worthy of subsequent clinical testing in phase II.

Keywords

Intranasal Administration Tizanidine Oral Tablet Nasal Administration Imidazoline Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This study was supported by MDM SpA. The authors do not have any conflict of interest to disclose.

References

  1. 1.
    John P, Khan IU, Akkurt M, et al. 5-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothia-diazol-4-amine (tizanidine). Acta Crystallogr Sect E Struct Rep Online. 2011;67:o838–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Wagstaff AJ, Bryson HM. Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997;53:435–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Lake AE 3rd, Saper JR. Chronic headache: new advances in treatment strategies. Neurology. 2002;59:S8–13.PubMedCrossRefGoogle Scholar
  4. 4.
    Muramatsu I, Kigoshi S. Tizanidine may discriminate between imidazoline-receptors and alpha 2-adrenoceptors. Jpn J Pharmacol. 1992;59:457–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Honda M, Sekiguchi Y, Sato N, et al. Involvement of imidazoline receptors in the centrally acting muscle-relaxant effects of tizanidine. Eur J Pharmacol. 2002;445:187–93.PubMedCrossRefGoogle Scholar
  6. 6.
    Bousquet P, Greney H, Bruban V, et al. I(1) imidazoline receptors involved in cardiovascular regulation: where are we and where are we going? Ann N Y Acad Sci. 2003;1009:228–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Salomone S, Waeber C. Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects. Front Pharmacol. 2011;2:9.PubMedGoogle Scholar
  8. 8.
    Delwaide PJ, Pennisi G. Tizanidine and electrophysiologic analysis of spinal control mechanisms in humans with spasticity. Neurology. 1994;44:S21–7.PubMedGoogle Scholar
  9. 9.
    Danzebrink RM, Gebhart GF. Antinociceptive effects of intrathecal adrenoceptor agonists in a rat model of visceral nociception. J Pharmacol Exp Ther. 1990;253:698–705.PubMedGoogle Scholar
  10. 10.
    Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess. 2003;7:1–111.Google Scholar
  11. 11.
    Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004;28:140–75.PubMedCrossRefGoogle Scholar
  12. 12.
    Dones I, Nazzi V, Broggi G. The guidelines for the diagnosis and treatment of spasticity. J Neurosurg Sci. 2006;50:101–5.PubMedGoogle Scholar
  13. 13.
    Hoogstraten MC, van der Ploeg RJ, vd Burg W, et al. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta Neurol Scand. 1988;77:224–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Delwaide PJ. Electrophysiological analysis of the mode of action of muscle relaxants in spasticity. Ann Neurol. 1985;17:90–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Lataste X, Emre M, Davis C, et al. Comparative profile of tizanidine in the management of spasticity. Neurology. 1994;44:S53–9.PubMedGoogle Scholar
  16. 16.
    Knutsson E, Martensson A, Gransberg L. Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis. J Neurol Sci. 1982;53:187–204.PubMedCrossRefGoogle Scholar
  17. 17.
    Mathias CJ, Luckitt J, Desai P, Baker H, el Masri W, Frankel HL. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. J Rehabil Res Dev. 1989;26:9–16.PubMedGoogle Scholar
  18. 18.
    Berry H, Hutchinson DR. A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain. J Int Med Res. 1988;16:75–82.PubMedGoogle Scholar
  19. 19.
    Tse FL, Jaffe JM, Bhuta S. Pharmacokinetics of orally administered tizanidine in healthy volunteers. Fundam Clin Pharmacol. 1987;1:479–88.PubMedCrossRefGoogle Scholar
  20. 20.
    Heazlewood V, Symoniw P, Maruff P, et al. Tizanidine—initial pharmacokinetic studies in patients with spasticity. Eur J Clin Pharmacol. 1983;25:65–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. 2007;337:1–24.PubMedCrossRefGoogle Scholar
  22. 22.
    ICH. Guidance for industry: E6 good clinical practice: consolidated guidance. April 1996. http://www.fda.gov/downloads/Drugs/Guidances/ucm073122.pdf. Accessed 19 Sep 2013.
  23. 23.
    Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. CMP/EWP/QWP/1401/98. London: EMEA; 2000.Google Scholar
  24. 24.
  25. 25.
    Nirogi RV, Kandikere VN, Shukla M, et al. Quantification of tizanidine in human plasma by liquid chromatography coupled to tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006;20:2286–92.PubMedCrossRefGoogle Scholar
  26. 26.
    Granfors MT, Backman JT, Laitila J, et al. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol. 2004;57:349–53.PubMedCrossRefGoogle Scholar
  27. 27.
    Browning SL, Tarekegn A, Bekele E, et al. CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme. Pharmacogenet Genomics. 2010;20:647–64.PubMedCrossRefGoogle Scholar
  28. 28.
    Momo K, Homma M, Osaka Y, et al. Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2010;50:331–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Neuvonen PJ. Towards safer and more predictable drug treatment—reflections from studies of the first BCPT prize awardee. Basic Clin Pharmacol Toxicol. 2012;110:207–18.PubMedCrossRefGoogle Scholar
  30. 30.
    Granfors MT, Backman JT, Laitila J, et al. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther. 2005;78:400–11.PubMedCrossRefGoogle Scholar
  31. 31.
    Granfors MT, Backman JT, Neuvonen M, et al. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther. 2004;76:598–606.PubMedCrossRefGoogle Scholar
  32. 32.
    Granfors MT, Backman JT, Neuvonen M, et al. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther. 2004;75:331–41.PubMedCrossRefGoogle Scholar
  33. 33.
    Backman JT, Granfors MT, Neuvonen PJ. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol. 2006;62:451–61.PubMedCrossRefGoogle Scholar
  34. 34.
    Gelber DA, Good DC, Dromerick A, et al. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke. 2001;32:1841–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Nance PW, Sheremata WA, Lynch SG, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol. 1997;54:731–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Henney HR 3rd, Runyan JD. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients. Int J Clin Pract. 2008;62:314–24.PubMedCrossRefGoogle Scholar
  37. 37.
    Emre M, Leslie GC, Muir C, et al. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). J Neurol Neurosurg Psychiatry. 1994;57:1355–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Daniela Cristina Vitale
    • 1
  • Cateno Piazza
    • 1
  • Tiziana Sinagra
    • 1
    • 2
  • Vincenzo Urso
    • 1
    • 2
  • Francesco Cardì
    • 3
  • Filippo Drago
    • 2
  • Salvatore Salomone
    • 1
    • 2
    Email author
  1. 1.Pharmacokinetic Unit, Unifarm Research CenterCataniaItaly
  2. 2.Department of Clinical and Molecular Biomedicine, Section of Pharmacology and BiochemistryCatania UniversityCataniaItaly
  3. 3.Polyclinic Vittorio Emanuele, University of CataniaCataniaItaly

Personalised recommendations